Literature DB >> 6633975

Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: selective loss of the intermediate (10S) form.

J R Atack, E K Perry, J R Bonham, R H Perry, B E Tomlinson, G Blessed, A Fairbairn.   

Abstract

Using density gradient centrifugation, three molecular forms of acetylcholinesterase have been distinguished in both normal and senile dementia of Alzheimer-type (SDAT) postmortem neocortex. Whilst the levels of the light and heavy forms were unaltered in SDAT there was a selective and extensive loss of the intermediate form. This form is predominantly hydrophobic and its loss from the cerebral cortex in SDAT may reflect degeneration of cholinergic axonal processes. This is the first report of an altered distribution of acetylcholinesterase molecular forms in a disease of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6633975     DOI: 10.1016/0304-3940(83)90302-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  29 in total

1.  Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data.

Authors:  K J Reinikainen; P J Riekkinen; L Paljärvi; H Soininen; E L Helkala; J Jolkkonen; M Laakso
Journal:  Neurochem Res       Date:  1988-02       Impact factor: 3.996

2.  Age-related changes in acetylcholinesterase and its molecular forms in various brain areas of rats.

Authors:  A Meneguz; G M Bisso; H Michalek
Journal:  Neurochem Res       Date:  1992-08       Impact factor: 3.996

3.  Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP.

Authors:  M Dumont; R Lalonde; J-F Ghersi-Egea; K Fukuchi; C Strazielle
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

4.  Effect of long-term exposure to aluminum on the acetylcholinesterase activity in the central nervous system and erythrocytes.

Authors:  R R Kaizer; M C Corrêa; L R S Gris; C S da Rosa; D Bohrer; V M Morsch; Maria Rosa Chitolina Schetinger
Journal:  Neurochem Res       Date:  2008-05-10       Impact factor: 3.996

Review 5.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 6.  Molecular biological search for human genes encoding cholinesterases.

Authors:  H Soreq; A Gnatt
Journal:  Mol Neurobiol       Date:  1987 Spring-Summer       Impact factor: 5.590

7.  Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease.

Authors:  J Sirviö; R Kutvonen; H Soininen; P Hartikainen; P J Riekkinen
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

8.  Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains.

Authors:  M A Morán; E J Mufson; P Gómez-Ramos
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Preferential inhibition of acetylcholinesterase molecular forms in rat brain.

Authors:  N Ogane; E Giacobini; E Messamore
Journal:  Neurochem Res       Date:  1992-05       Impact factor: 3.996

10.  Altered levels of acetylcholinesterase in Alzheimer plasma.

Authors:  María-Salud García-Ayllón; Iolanda Riba-Llena; Carol Serra-Basante; Jordi Alom; Rathnam Boopathy; Javier Sáez-Valero
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.